Big Pharma Cash Grab? New Alzheimer’s Blood Test Raises Big Questions
Big Pharma has a bad habit of rushing medical breakthroughs to market.
We’ve seen it with drugs that turned out to be ineffective, dangerous, or both. We saw it with Alzheimer’s drugs like Aduhelm, which was fast-tracked despite lack of proof it actually worked.
Now, it looks like history is repeating itself.
A new Alzheimer’s blood test—once hailed as a game-changer—may not be as reliable as promised.
Why? Because the “Alzheimer’s markers” these tests detect aren’t just found in the brain…
For years, researchers believed that phosphorylated tau proteins (p-tau 181 and p-tau 217) were exclusive markers of Alzheimer’s disease. These proteins build up in the brains of people with Alzheimer’s, contributing to cognitive decline.
So naturally, blood tests looking for these proteins were supposed to provide a fast, easy way to diagnose the disease.
But now, new research blows that theory apart.
A shocking study from the University of Halle in Germany found that these same “Alzheimer’s markers” are also released by damaged muscles.
That’s right—these tau proteins aren’t just from the brain. They’re also found in the blood of ALS patients—a completely different disease that attacks the muscles, not memory.
This huge flaw in the Alzheimer’s blood test could have disastrous consequences:
- False Diagnoses: People with ALS, muscle damage, or even extreme exercise could test positive for Alzheimer’s—even if they don’t have it.
- Unnecessary Treatments: A false diagnosis could push healthy people into taking risky, expensive drugs—ones with terrible side effects.
- More Money for Big Pharma: Every false positive means more patients, more prescriptions, and more profits—for a test that might not even be accurate.
We’ve seen this pattern time and time again…
Step 1: Hype a “revolutionary” new treatment.
Step 2: Rush it through approvals, even if the science isn’t solid.
Step 3: Make billions before anyone figures out the flaws!
They’ve done it with countless drugs. Now, it looks like they’re doing it again—this time with blood tests that could mislead millions.
Alzheimer’s is a devastating disease, and early detection is important.
But an inaccurate test isn’t the answer!
Before jumping on the latest “breakthrough,” here’s what you should do:
- Demand better science. The rush to market should never outweigh accuracy and patient safety.
- Look beyond Big Pharma. Natural brain health solutions don’t come with billion-dollar price tags—but they can make a real difference.
- Support your brain with natural tools. While scientists sort out the flawed blood test mess, focus on real, proven ways to keep your brain strong.
It’s yet another reminder: When Big Pharma rushes something to market, follow the money.
Because when profits are on the line, your health is just an afterthought.
To remaining cautiously optimistic,
Rachel Mace
Managing Editorial Director, e-Alert
with contributions from the research team
P.S. Does a happy gut equal a happy brain? Science says yes! Learn more here.
Sources:
Staff, S. (2025, March 10). Researchers uncover serious flaw in promising Alzheimer’s blood tests. Study Finds. https://studyfinds.org/researchers-uncover-serious-flaw-in-promising-alzheimers-blood-tests/
